UK Markets open in 4 mins

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
285.94-0.46 (-0.16%)
At close: 04:00PM EST
286.31 +0.37 (+0.13%)
After hours: 07:25PM EST
Full screen
Trade prices are not sourced from all markets
Previous close286.40
Open288.00
Bid0.00 x 800
Ask0.00 x 800
Day's range279.91 - 288.09
52-week range200.84 - 296.67
Volume2,836,595
Avg. volume2,833,263
Market cap161.06B
Beta (5Y monthly)0.58
PE ratio (TTM)23.68
EPS (TTM)12.07
Earnings date06 Feb 2023 - 10 Feb 2023
Forward dividend & yield7.76 (2.98%)
Ex-dividend date17 Aug 2022
1y target est254.85
  • Bloomberg

    Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J

    (Bloomberg) -- Horizon Therapeutics Plc rose by the most in more than three years after the drug developer disclosed it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatStock Traders Cheer Powell’s Risk-Friendly Shift: Markets WrapNYC Becomes One Billionaire Family’s Haven From China Property Crash

  • Motley Fool

    Why Horizon Therapeutics Stock Is Skyrocketing Today

    Shares of Horizon Therapeutics (NASDAQ: HZNP) were skyrocketing 27.2% higher as of 10:48 a.m. ET on Wednesday. The big jump came after the company announced Thursday evening that it's in discussions with Amgen (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ) subsidiary Janssen, and Sanofi (NASDAQ: SNY) about potentially being acquired. There were two words in Horizon's press release that investors should note: "highly preliminary."

  • Reuters

    J&J sues Amgen over plan to sell drug similar to blockbuster Stelara

    (Reuters) -Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market a drug for ulcerative colitis and other conditions similar to J&J's top-selling Stelara, saying it would infringe two patents in a lawsuit made public on Wednesday. Stelara accounted for $9.1 billion of J&J's $52 billion in global drug sales last year. It is a biologic drug, meaning it is made inside living cells.